Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean D. taghvaei (3 results)?
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.
Dabagian H, Taghvaee T, Martorano P, Martinez D, Samanta M, Watkins CM, Chai R, Mansfield A, Graham TJ, Maris JM, Pryma DA, Mach RH, Makvandi M. Dabagian H, et al. ACS Pharmacol Transl Sci. 2021 Jan 26;4(1):344-351. doi: 10.1021/acsptsci.0c00206. eCollection 2021 Feb 12. ACS Pharmacol Transl Sci. 2021. PMID: 33615184 Free PMC article.
Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd.
Vaziri M, JavadzadehShahshahani H, Moghaddam M, Taghvaee N. Vaziri M, et al. Iran J Ped Hematol Oncol. 2015;5(2):93-9. Epub 2015 Apr 20. Iran J Ped Hematol Oncol. 2015. PMID: 26131348 Free PMC article.
Only 4% (n=4) had developed alloantibodies. (One patient developed dual alloantibody (Anti-C and Anti-D) and three patients developed single alloantibody (Anti-K)).Gel method detected 4 patients with alloantibody but in two patients not detected by the standard tube method …
Only 4% (n=4) had developed alloantibodies. (One patient developed dual alloantibody (Anti-C and Anti-D) and three patients developed …